Stroke Risk Lowered With Vorapaxar in Patients With Prior MI, PAD

Share this content:
Stroke risk lowered with vorapaxar in patients with prior MI, PAD
Stroke risk lowered with vorapaxar in patients with prior MI, PAD
Vorapaxar reduced the risk for ischemic stroke in patients with a history of MI or peripheral arterial disease, according to new data from the TRA 2P-TIMI 50 trial. Researchers also found no significant increase in risk for hemorrhagic conversion or death among patients who had an ischemic stroke while taking vorapaxar (Zontivity, Merck), an antiplatelet agent approved by the FDA in May.
READ FULL ARTICLE From HealIO
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »